Psilocybin Content by Psilocybe Cubensis Strain

Share this post:

LinkedIn
Facebook
X
Reddit
WhatsApp
Print

Psilocybin content differed across the five tested Psilocybe cubensis samples, with measured psilocybin ranging from 6.134 to 9.0435 mg/g of dry weight. Combined psilocybin and psilocin ranged from 0.649% to 0.956%. These figures are single-sample laboratory results for five strains in a larger genetic library. They show measured variation across the samples and do not establish a fixed potency range for each strain.

Psilocybe cubensis strain potency comparison

The comparison uses dried mushroom fruiting-body samples analyzed by ACS Laboratory. Samples were collected and analyzed between September 21 and September 26, 2023. Each row represents one tested sample from one named strain.

Strain samplePsilocybin mg/gPsilocybin dry weightPsilocin mg/gPsilocin dry weightCombined psilocybin and psilocinTotal measured alkaloidsMoisture
Sacred Sun 2-P29.04350.904%0.5220.0522%0.956%1.0213%6.12%
Old Dirty PE 1-P18.1180.812%0.1300.0130%0.825%0.895%6.50%
Blue Meanie 4-P46.9910.699%0.2750.0275%0.727%0.823%6.45%
DC MAK 5-P56.3220.632%0.5380.0538%0.686%0.745%5.88%
Hawaiian 3-P36.1340.613%0.3640.0364%0.649%0.697%5.94%

The table is ordered by combined psilocybin and psilocin. ACS reported concentrations on a dry-weight basis. Total measured alkaloids include psilocybin, psilocin, baeocystin, norbaeocystin, norpsilocin, aeruginascin and 4-Hydroxy-TMT.

Measured potency range across the five samples

The public dataset produced the following observed ranges.

MeasurementLowest resultHighest resultObserved range across samples
Psilocybin6.134 mg/g9.0435 mg/g6.134 to 9.0435 mg/g
Psilocybin dry weight0.613%0.904%0.613% to 0.904%
Psilocin0.130 mg/g0.538 mg/g0.130 to 0.538 mg/g
Psilocin dry weight0.0130%0.0538%0.0130% to 0.0538%
Combined psilocybin and psilocin0.649%0.956%0.649% to 0.956%
Total measured alkaloids0.697%1.0213%0.697% to 1.0213%

Sacred Sun 2-P2 produced the highest psilocybin result and the highest combined result in this set. Hawaiian 3-P3 produced the lowest figures for both measurements. The Sacred Sun combined concentration was about 47% higher than the Hawaiian result.

This comparison describes the five samples submitted for testing. Repeated samples from several harvests would be needed to calculate a strain-specific average, distribution and tested range.

What the five strain results show

Sacred Sun 2-P2 had the highest combined result

Sacred Sun contained 9.0435 mg/g of psilocybin and 0.522 mg/g of psilocin. Its combined concentration reached 0.956% of dry weight. Total measured alkaloids reached 1.0213%.

The sample also contained 0.488 mg/g of baeocystin, 0.061 mg/g of norbaeocystin, 0.0555 mg/g of norpsilocin, 0.0289 mg/g of aeruginascin and 0.0175 mg/g of 4-Hydroxy-TMT. Its 4-Hydroxy-TMT result was the highest among the five samples.

Old Dirty PE 1-P1 had high psilocybin and low psilocin

Old Dirty PE contained 8.118 mg/g of psilocybin, the second-highest result in the table. Its psilocin result was 0.130 mg/g, the lowest of the five samples. Combined psilocybin and psilocin reached 0.825%. Total measured alkaloids reached 0.895%.

This pattern shows why total psilocybin alone does not describe the entire alkaloid profile. Two samples with similar total potency can distribute their measured compounds in different ratios.

Blue Meanie 4-P4 had the highest baeocystin result

Blue Meanie contained 6.991 mg/g of psilocybin and 0.275 mg/g of psilocin. Its combined concentration was 0.727%, placing it third among the five tested samples.

The sample contained 0.800 mg/g of baeocystin, the highest baeocystin result in the set. Its norbaeocystin result of 0.102 mg/g was also the highest. Those figures gave Blue Meanie a total measured alkaloid concentration of 0.823%.

DC MAK 5-P5 had the highest psilocin result

DC MAK contained 6.322 mg/g of psilocybin and 0.538 mg/g of psilocin. Its psilocin value was the highest in the set, even though its psilocybin value ranked fourth. Combined psilocybin and psilocin reached 0.686%.

DC MAK also produced the highest norpsilocin result at 0.0678 mg/g. The sample shows how individual alkaloid rankings can differ from the psilocybin ranking.

Hawaiian 3-P3 had the lowest combined result

Hawaiian contained 6.134 mg/g of psilocybin and 0.364 mg/g of psilocin. Its combined concentration was 0.649%. Total measured alkaloids reached 0.697%.

The result identifies the concentration in this submitted sample. Cultivation records and repeated chemical analysis are needed before you can describe typical performance for the wider genetic line.

Minor alkaloid profiles also differed

The five ACS reports measured five compounds in addition to psilocybin and psilocin.

Strain sampleBaeocystin mg/gNorbaeocystin mg/gNorpsilocin mg/gAeruginascin mg/g4-Hydroxy-TMT mg/g
Sacred Sun 2-P20.4880.06100.05550.02890.0175
Old Dirty PE 1-P10.5660.07810.01030.03980.00439
Blue Meanie 4-P40.8000.10200.03290.02490.00545
DC MAK 5-P50.4500.05370.06780.01480.0104
Hawaiian 3-P30.3600.04390.03500.02430.00829

You can see different chemical profiles even within a small group of P. cubensis samples. Blue Meanie led the set in baeocystin and norbaeocystin. DC MAK led in norpsilocin. Old Dirty PE led in aeruginascin. Sacred Sun led in 4-Hydroxy-TMT.

These profile differences do not establish distinct subjective or clinical effects. Human research has not defined the contribution of each minor alkaloid at these concentrations. The results support chemical comparison and future study.

How to read psilocybin percentages and mg/g

A dry-weight percentage tells you how much of a dried sample consists of a measured compound. A concentration of 1% equals 10 mg/g. Sacred Sun measured 0.904% psilocybin, which corresponds to about 9.04 mg/g.

You should keep three units separate when reading a report.

  • mg/g gives milligrams of a compound per gram of dried sample
  • Dry-weight percentage gives the same concentration as a percentage
  • Milligrams per package gives the total amount in the tested package

Package totals depend on package weight. They are less useful for comparing samples of different sizes. The mg/g and dry-weight percentage columns allow a direct concentration comparison.

The combined psilocybin and psilocin figure in these reports is a simple sum of their dry-weight percentages. Psilocybin and psilocin have different molecular weights and pharmacology. The combined percentage provides a useful composition figure. It should not be treated as a complete measure of expected human response.

Strain name alone cannot predict potency

A Psilocybe cubensis strain name identifies a cultivated line or market label. Naming practices are not standardized across all cultivators. Two cultures sold under the same familiar name may have different genetic histories, selection records and chemical profiles.

Even a verified genetic line can produce variable alkaloid concentrations. Genetics affect biosynthetic capacity. Cultivation conditions affect expression. Relevant variables include substrate, temperature, humidity, air exchange, harvest timing, flush number, fruiting-body part, drying and storage.

A controlled 2026 study of 14 P. cubensis strains found more than sevenfold differences in total tryptamines across strains grown under the same conditions. The researchers also tested five individual fruiting bodies from selected strains. Within-strain coefficients of variation ranged from about 13% to 23%.

An earlier study of psilocybin-producing mushroom collections also found wide differences in tryptamine concentrations across species and samples. Together, these results show why you need chemical data from the tested batch.

Drying, moisture and storage affect comparison

The five ACS samples had moisture levels from 5.88% to 6.50%. This narrow span supports a more direct dry-weight comparison because the samples were similarly dried.

Moisture still needs to appear in the data. A wetter sample contains more water per gram, which can lower an as-received concentration. Dry-weight reporting corrects for this effect and makes samples easier to compare.

Post-harvest handling can also change measured alkaloids. A Psilocybe cubensis stability study found changes after tissue damage, drying, grinding and storage. Psilocybin, psilocin and minor compounds did not change at identical rates under every condition.

For repeated strain testing, you need consistent harvest, drying, storage and sampling procedures. A genetic label linked to cultivation metadata gives you a stronger dataset than a name linked to one isolated result.

Conclusion

To create a true potency range for one strain, you need several representative samples from separate fruiting bodies, harvests and batches. The test plan should use the same analytical method and report results on the same basis.

A useful strain dataset records the following fields.

  • Verified genetic identifier
  • Cultivation batch and harvest date
  • Substrate and controlled growing conditions
  • Flush number and fruiting-body part
  • Drying and storage method
  • Moisture at testing
  • Psilocybin, psilocin and minor alkaloids in mg/g
  • Mean, median, minimum, maximum and standard deviation

Single-sample results remain useful as measured observations. Their role is to establish what the laboratory found in that submitted material. Repeated testing shows how a strain performs across time and production conditions.

As you compare strain potency data, we at Rose Hill Life Sciences work as a psychedelic research organization focused on the production and research of Psilocybe cubensis. We maintain a proprietary library of more than 50 genetic strains and link strain identity with cultivation and chemical records. Our Massachusetts research work sits at the intersection of psychedelic science and therapeutic integration, with ACS testing used to document the five public strain samples presented here.

Disclaimer: The information in this article is for educational and informational purposes only and does not constitute medical advice.

You May Also Like

Bryan Smith

Research & Development

Bryan Smith is an accomplished biotech leader in small molecule drug discovery and development. With over 18 years of experience at Deciphera Pharmaceuticals, he last served as Vice President of Biological Sciences and Research Site Head, until their acquisition by Ono Pharmaceutical in 2024. His work directly contributed to the discovery and development of FDA-approved therapies Qinlock™ (ripretinib) and Romvimza™ (vimseltinib), along with multiple additional compounds advancing through clinical trials.

In 2024, Bryan transitioned to independent consulting and scientific advisory roles. Through Smith Biotech Consulting LLC, he provides expert guidance on all phases of drug discovery, preclinical/clinical planning, IND/NDA support, due diligence, and pipeline strategy. Bryan holds a PhD in Biochemistry from the University of Wisconsin-Madison.  

Adam Goodman

Advisor

Adam is a seasoned entrepreneur with a wealth of experience in spearheading real estate development and management endeavors. His focus primarily lies in land development, where he orchestrates the intricate tapestry of planning and zoning entitlements, while meticulously overseeing all facets of engineering and architectural design, leasing, construction, and financing.

With a national reach spanning 23 states and encompassing over 250 properties, totaling more than 6 million square feet, Adam’s proficiency in navigating the complexities of the industry is evident.

Beyond real estate, Adam’s endeavors extend into the realm of alternative investments, boasting successful ventures in healthcare, professional sports franchises, financial services, diverse agricultural platforms, and the stewardship of local restaurants.

 

Rotem Petranker, PhD, Psychology

Psychedelic Researcher

Rotem Petranker is a psychedelics researcher with a particular emphasis on microdosing, therapy, research methods and research ethics. He earned his BSc from the University of Toronto, his Master’s degree from York University, and his PhD from McMaster University.

As part of my research, I have gained extensive expertise in navigating the regulatory landscapes of Health Canada and the FDA and a strong background in designing rigorous clinical trial research methodologies. 

I founded the Canadian Centre for Psychedelic Science in 2018, established the Psychedelic Science Research Program at the University of Toronto in 2019, and, more recently, ran the largest clinical trial to date on the effectiveness of microdosing psilocybin for Major Depressive Disorders. I have published many papers on microdosing, including some of the largest samples in the literature and some that have set standards for performing psychedelic research.

Kevin Bourke

Chief Commercial Officer

Kevin Bourke is a dynamic executive and strategic planner whose career spans over two decades of crafting and elevating world-class Jamaican brands and transformational experiences on the global stage. With a keen understanding of culture, identity, and international markets, he has played a pivotal role in shaping some of Jamaica’s most iconic names — including Appleton Estate Rum, Chris Blackwell’s Rum, and Usain Bolt’s Tracks & Records — bringing them from local roots to international acclaim. His leadership and vision have also been instrumental in major cultural movements such as Fiction and the internationally recognized TmrwTday Wellness Festival.

An innovator at heart, Mr. Bourke seamlessly blends brand strategy with deep cultural resonance. His ability to connect with diverse audiences has established these brands not only as commercial successes but as symbolic ambassadors of Jamaican excellence, fortifying the island’s influence in beverage, music, lifestyle, and experiential sectors.

In recent years, Kevin has steered his strategic acumen toward the cutting-edge psilocybin and wellness industry, becoming a co-founder and Chief Marketing and Branding Officer of Rose Hill, Jamaica’s leading cultivator, exporter, and innovator of psilocybin products and experiences. Through ventures like ONE Retreats, he has helped craft safe, guided psychedelic-assisted healing programs that attract participants from around the world seeking deep personal transformation, including military veterans and international wellness seekers.

Kevin’s impact extends beyond business into industry shaping and policy, as he sits on the Jamaica Psilocybin Mushroom Industry Technical Committee (under the Bureau of Standards) — a pivotal body that is formalizing guidelines and regulatory standards for the emerging legal psilocybin sector in Jamaica. His presence on this committee underscores his leadership role in ensuring the industry’s integrity, safety, and sustainable growth.

Highly regarded for his extensive network throughout Jamaica and internationally, Kevin remains passionately committed to advancing ethical, high-integrity product development and customer-centric experiences at every level. His dedication is driven not only by professional achievement but by a deep vision for human well-being, cultural celebration, and the global evolution of plant-based healing.

Jama Pitman

Chief Executive Officer

Jama Pitman is a seasoned biopharmaceutical executive with extensive expertise in global drug development and commercialization. With over two decades of experience, she has contributed to the development of groundbreaking therapies across oncology, rare diseases, and antivirals. As a strategic leader, she has successfully transitioned companies from private to public markets, navigated complex M&A transactions, and driven innovative drug approvals.

Jama has held executive roles in leading organizations, including Deciphera Pharmaceuticals, where she played a pivotal role in scaling operations from a small, privately held biotech company to a global, multi-product company acquired for $2.4 billion. She brings exceptional skills in regulatory affairs, portfolio management, quality assurance, and clinical operations, longside a proven track record of fostering inclusivity and mentorship within her teams.

Currently, as the founder of JP BioPharma Consulting, Jama advises biopharma and tech companies on accelerating drug development and achieving corporate goals. Her collaborative and forward-thinking approach aligns seamlessly with Rose Hill’s mission to advance transformative therapies in mental health and beyond.

Education: B.Sc. in Microbiology, University of New Hampshire.

Notable Achievements: Contributed to the development of multiple FDA-approved therapies, including QINLOCK® for gastrointestinal stromal tumors.

Domenic Suppa

Chief Operating Officer

Domenic is co-founder and the Operations Chief of Rose Hill Health Holdings.

He has been working as a Cannabis technology and operations veteran with more than 11 years’ experience as a senior executive in an operationally complex, and highly regulated industry.

His introduction and entrance into the Cannabis sector started in 2010 with a seed investment into a Denver-based vertically integrated cannabis company called, Evolab. He served as C.O.O. for 5 years from 2013-2018, through the eventual acquisition by Harvest Health and Recreation (HARV: CSE).

Domenic moved on to be acting COO of the manufacturing division for Supreme Cannabis (CSE: FIRE) and supported the acquisition of BLISSCO (CSE: BLISS, a BC-based cannabis manufacturer). Domenic has worked with high-profile national cannabis brands including KKE, and Monogram, and retail brands in MA Native Sun, Terps, and Tilt. Domenic is a proven leader and team builder; his previous experiences have all been with early-stage and growth equity enterprises.

He has refined and evolved his leadership roles, including his team-building skills. He is a value creator. Domenic is a firm believer in training and continuous development. He excels in employing practices, tools, and methodologies designed to achieve maximum process efficiency while minimizing waste and delays.

 

Burton J. Tabaac

Clinical Development

Dr. Burton J. Tabaac, MD, FAHA, brings a wealth of expertise in neurology and stroke rehabilitation to Rose Hill. As an Associate Professor and Section Chief of Neurology at The University of Nevada’s Reno School of Medicine, and Medical Director of Stroke at Carson Tahoe Health, Dr. Tabaac has been at the forefront of innovative neurological treatments.

A graduate of the prestigious cerebrovascular neurology fellowship program at The Johns Hopkins University Hospital, Dr. Tabaac’s accolades include being a three-time recipient of The Arnold P. Gold Foundation’s Humanism and Excellence in Teaching Award and induction into the Alpha Omega Alpha Honor Medical Society.

He recently published an eight-part paper in the American Journal of Therapeutics reviewing psychedelics as therapeutics for primary care clinicians. Dr. Tabaac’s groundbreaking research focuses on the application of psychedelics in brain injury and stroke rehabilitation.

Dr. Tabaac was recently appointed by the Governor of Nevada to serve as a member of the state’s Psychedelic Medicines Working Group, which provides expertise and testimony relating to the therapeutic use of entheogens.

As the host of The Zero Hour Podcast, he engages with leading experts in psychedelic research. His commitment to advancing the field was further highlighted in his 2022 TEDx talk at UCLA, “Mental Health Meets Psychedelics.”

“Joining Rose Hill’s advisory team presents an exciting opportunity to further explore the potential of psilocybin in neurological recovery,” said Dr. Tabaac.

“The company’s commitment to ethical cultivation and research aligns perfectly with my vision for advancing patient care through innovative therapies. I’m eager to bring my expertise to Rose Hill and contribute to the evolving landscape of psychedelic medicine.”

Charles Lazarus

Mycologist

Mr. Lazarus boasts over 16 years of extensive expertise in psilocybin and cannabis, focusing on genetic development, cultivation, extraction, and operations logistics. Notably, he recently achieved a milestone by cultivating and delivering the largest legal shipment of premium psilocybin globally.

As an accomplished owner/operator, Mr. Lazarus has successfully managed multiple farming and harvesting businesses, earning commendations for his unwavering commitment to quality and impressive output volumes. Since 2015, he has been actively involved in producing proprietary psilocybin genetics and cultivation solutions tailored for the Jamaican market and large research and development clients.

His contributions span various aspects, including genetic development, cultivation, extraction, harvest, and logistics. Additionally, Mr. Lazarus owned and operated Island Fresh Ltd., a venture that played a pivotal role in exporting fresh fruit, ground provisions, and promoting brand Jamaica to the English market. Under his leadership, Island Fresh Ltd. achieved the highest volume from Jamaica for three consecutive years.

Mr. Lazarus’s extensive experience also includes serving as the Harvest Manager for cannabis grow operations in California from 2013 to 2017, further solidifying his comprehensive knowledge in the cannabis industry.